Uric acid lowering therapy in cardiovascular diseases

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• High serum uric acid (SUA) is increasingly recognized as an independent risk factor for hypertension and cardiovascular diseases (CVD), including ischemic heart disease and heart failure.
• Recent studies report an independent risk relationship between hyperuricemia, CVD, and mortality, with elevated SUA levels exacerbating mortality risk in gout patients.
• These findings have spurred research into the potential benefits of uric acid-lowering therapies for cardiovascular conditions.

Purpose of the Study:

• To review current human study evidence on the role of uric acid-lowering therapy in managing cardiovascular diseases.
• To explore the practical and clinical implications of these therapies.
• To discuss the underlying mechanisms contributing to hyperuricemia's detrimental effects and the benefits of its reduction.

Main Methods:

• Systematic review of clinical studies and human research.
• Analysis of evidence on uric acid-lowering drugs, particularly xanthine oxidase inhibitors.
• Examination of proposed mechanisms, including endothelial dysfunction and systemic inflammation.

Main Results:

• Clinical studies suggest beneficial effects of uric acid-lowering drugs in hypertension, ischemic heart disease, and heart failure.
• Evidence indicates hyperuricemia as an independent risk factor for acute myocardial infarction and overall mortality.
• The impact of SUA on mortality is dose-dependent, even within normal to high ranges.

Conclusions:

• Uric acid-lowering therapy shows promise in managing cardiovascular diseases.
• Endothelial dysfunction and systemic inflammation are key mechanisms linking hyperuricemia to cardiovascular risk.
• Further clinical application and research into these therapies are warranted for cardiovascular health.